Literature DB >> 26136162

Compound Passport Service: supporting corporate collection owners in open innovation.

David M Andrews1, Sébastien L Degorce2, David J Drake3, Magnus Gustafsson4, Kevin M Higgins3, Jon J Winter2.   

Abstract

A growing number of early discovery collaborative agreements are being put in place between large pharma companies and partners in which the rights for assets can reside with a partner, exclusively or jointly. Our corporate screening collection, like many others, was built on the premise that compounds generated in-house and not the subject of paper or patent disclosure were proprietary to the company. Collaborative screening arrangements and medicinal chemistry now make the origin, ownership rights and usage of compounds difficult to determine and manage. The Compound Passport Service is a dynamic database, managed and accessed through a set of reusable services that borrows from social media concepts to allow sample owners to take control of their samples in a much more active way.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Mesh:

Year:  2015        PMID: 26136162     DOI: 10.1016/j.drudis.2015.06.011

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  1 in total

1.  The creation and characterisation of a National Compound Collection: the Royal Society of Chemistry pilot.

Authors:  David M Andrews; Laura M Broad; Paul J Edwards; David N A Fox; Timothy Gallagher; Stephen L Garland; Richard Kidd; Joseph B Sweeney
Journal:  Chem Sci       Date:  2016-02-23       Impact factor: 9.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.